ArticleFrontiers in endocrinology2026
Visceral fat area as a predictor for macrovascular complications in patients with type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the association between visceral fat area (VFA) and markers of atherosclerosis in patients with type 2 diabetes mellitus (T2DM), with or without macrovascular complications (MVC). Additionally, the study sought to determine the optimal VFA threshold for predicting MVC in individuals with T2DM. Methods: This retrospective study included 1, 176 patients with T2DM and 289 healthy individuals enrolled between August 2018 and May 2022. Participants were classified into three groups: healthy controls, T2DM without MVC, and T2DM with MVC. Demographic characteristics, clinical parameters, and laboratory data were collected. VFA, carotid intima-media thickness (CIMT), and brachial-ankle pulse wave velocity (baPWV) were measured. Univariate analysis was conducted for variable selection, followed by multivariate logistic regression to identify independent predictors. A risk prediction model was constructed. Model calibration was assessed using the Hosmer-Lemeshow goodness-of-fit test, and predictive performance was evaluated using the area under the receiver operating characteristic curve (AUC). Results: Baseline comparisons across the three groups revealed a progressive increase in VFA from healthy controls to individuals with T2DM alone and to those with T2DM and MVC ( Conclusions: VFA is an independent predictor of MVC in patients with T2DM, demonstrating superior predictive value compared to traditional indicators such as BMI. The predictive model developed in this study shows high accuracy, supporting early identification of high-risk individuals and enabling implementation of personalized interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.